Skip to main content
. 2020 Nov 12;10:19736. doi: 10.1038/s41598-020-76875-9

Figure 1.

Figure 1

Circulating CLU levels in subjects among different groups. (A) Healthy controls and BA patients. (B) BA subgroups including non-jaundice and jaundice. (C) BA patients with mild fibrosis (F0–F2) and severe fibrosis (F3–F4). (D) BA patients according to severity of hepatic damage (ALT values).